Table 3.
Univariate performance of CT models
| Model | Complete cohort | Active treatment cohort | ||||
|---|---|---|---|---|---|---|
| R2 | AUC (95% CI) | p value | R2 | AUC (95% CI) | p value | |
| 6-month mortality | ||||||
| Marshall | 0.402 | 0.815 (0.715–0.914) | 0.046 | 0.247 | 0.750 (0.612–0.888) | 0.362 |
| Rotterdam | 0.348 | 0.774 (0.669–0.879) | 0.003 | 0.119 | 0.654 (0.509–0.799) | 0.037 |
| Stockholm | 0.459 | 0.850 (0.827–0.973) | 0.089 | 0.287 | 0.783 (0.653–0.912) | 0.390 |
| Helsinki | 0.601 | 0.900 (0.762–0.938) | Ref | 0.368 | 0.816 (0.694–0.939) | Ref |
| 6-month unfavorable outcome* | ||||||
| Marshall | 0.574 | 0.887 (0.802–0.971) | Ref | 0.498 | 0.849 (0.742–0.957) | Ref |
| Rotterdam | 0.519 | 0.846 (0.744–0.947) | 0.116 | 0.443 | 0.825 (0.710–0.941) | 0.366 |
| Stockholm | 0.507 | 0.871 (0.776–0.967) | 0.769 | 0.407 | 0.833 (0.718–0.949) | 0.802 |
| Helsinki | 0.502 | 0.868 (0.787–0.949) | 0.653 | 0.363 | 0.800 (0.685–0.915) | 0.391 |
Differences in AUC were compared using the DeLong test. AUC, area under the curve; CI, confidence interval; GOS, Glasgow Outcome Scale
*Defined as GOS 1–3; missing for 4 patients